The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.
Challenging the “One-Size-Fits-All” Approach in Early MCL Treatment
June 19th 2022Anita Kumar, MD, medical oncologist with Memorial Sloan Kettering Cancer Center, led a session at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO), on New Directions in Mantle Cell Lymphoma.
Read More
Parental Age May Be Linked With Childhood Cancer Risk, but More Research Is Needed
June 14th 2022A recent meta-analysis aimed to clarify the relationship between parental age and solid tumor pediatric cancers, but more studies are necessary to overcome the limitations of available research.
Read More
Novel Prognostic Biomarkers Indicate Prognosis in Acute Myeloid Leukemia
June 6th 2022A novel prognostic model based on N 6-methyladenosine-associated long non-coding RNAs demonstrated accuracy in determining high- and low-risk disease, suggesting the associated risk value may have potential as a novel biomarker.
Read More
FDA Approves Tisa-Cel for Third Indication, R/R Follicular Lymphoma
May 31st 2022Tisagenlecleucel (tisa-cel) was approved to treat adults with relapsed or refractory (R/R) follicular lymphoma. This is the third indication for the therapy since it became the first FDA-approved chimeric antigen receptor T-cell therapy in 2017.
Read More
Review Addresses Antifungal Prophylaxis in AML and Provides Guidance for Novel Agents
May 9th 2022Patients with acute myeloid leukemia (AML) who have undergone intensive chemotherapy are at a very high risk for invasive fungal disease, and a changing treatment landscape warrants further research on drug-drug interactions and outcomes.
Read More
Hypomethylating Agents With Venetoclax Can Be Effective Bridge to Transplant in AML
May 1st 2022Among a cohort of 88 patients with acute myeloid leukemia who received hypomethylating agents with venetoclax prior to allogeneic hematopoietic cell transplant, 85% had achieved morphologic complete response at 100 days.
Read More
AKR1C3 Expression May Hold Potential as a Biomarker, Clinical Target in T-ALL
April 24th 2022Aldo-keto reductase 1C3 (AKR1C3) has been identified as a potential biomarker and target in several cancers, and a recent study found it to be a potential biomarker in T acute lymphoblastic leukemia/lymphoma (T-ALL).
Read More
Neurocognitive Changes After CAR T-Cell Therapy for NHL Similar to Other Cancers
April 20th 2022With an increasing number of longer-term survivors treated with chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma (NHL), more research is needed to confirm its effects on neurocognitive performance.
Read More
City of Hope’s Alvarnas: Payers Must Recognize Cancer Care Is Different
April 17th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope in Duarte, California, spoke March 4 at the closing session of the Association for Community Cancer Centers (ACCC) Annual Meeting & Cancer Business Summit in Washington, DC.
Read More
Pretreatment PROs May Have Survival Implications in DLBCL, Finds Exploratory Study
April 12th 2022The researchers found that the prognostic values for both overall and progression-free survival remained even after adjusting for the International Prognostic Index, a widely used prognostic model of outcomes for the disease.
Read More
Nearly One-Fourth of DLBCL Cases May Be Attributable to Obesity in Young Adulthood, Says Study
April 8th 2022Across all measures, researchers found that body mass index in young adults had the strongest association with the risk of non-Hodgkin lymphoma (NHL), estimating that 23.3% of diffuse large B-cell lymphoma (DLBCL) cases and 11% of NHLs overall can be attributed to obesity.
Read More
High CD47 Expression on HRS Cells Carries Poor Survival Implications in Classical HL
March 27th 2022Retrospective study findings show that CD47 expression on Hodgkin and Reed–Sternberg (HRS) cells varied between patients who had classical Hodgkin lymphoma (HL) and was associated with poor outcomes.
Read More